Court Rules in Shire's Favor, Bans Proposed Generic Adderall Variant

   By Carlo Martuscelli

Shire PLC (SHP.LN) said Friday that a U.S. district court has ruled that a generic version of Adderall XR--for which a rival company had filed a new drug application--violates Shire patents, and wouldn't be allowed on the market.

The Irish-headquartered pharmaceutical company said that the Massachusetts court had ruled against competitor Abhai LLC because the proposed generic medication was in violation of a number of Shire patents. Therefore Abhai won't be allowed to bring the product to market until those patents expired.

Shire also said that the court had sanctioned Abhai for litigation misconduct, and ordered that a copy of the court's opinion be sent to the U.S. Food and Drug administration, in light of what the court said was Abhai's "pervasive corporate unwillingness to play by the rules."

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

March 23, 2018 05:50 ET (09:50 GMT)

Shire Plc ADS, Each Representing Three Ordinary Shares (NASDAQ:SHPG)
Historical Stock Chart
From Mar 2024 to Apr 2024